We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Brazilian IVD Market Fueled by Growing Demand

By LabMedica International staff writers
Posted on 03 Jul 2017
Print article
Brazil's in vitro diagnostic (IVD) market is one of the largest, driven by increasing interest in molecular testing technologies, prenatal screening, and point-of-care (POC) glucose testing. Brazil, which has a growing middle class, stabilizing economy, increasing urban population, and a supportive government, is witnessing a major shift toward the private health industry, which supports the growth of IVD technologies that are expensive or not typically covered at the public level. These are the latest findings of Kalorama Information, (New York, NY, USA), an independent medical market research firm.

Brazil is the world’s sixth most populated country with 205.8 million people residing in the country in 2016 and has a market worth over USD 900 million. Brazil is also the largest country in Latin America in terms of population, accounting for a share of 33% of the region's total population. Brazil’s population distribution is expected to shift toward the 65 years and above age group, which will account for 21% of its total population by 2050, up from 7% in 2010. This shift in the country’s aging population is expected to lead to an increase in the incidence of diseases, as an aging population is more vulnerable to illness.

The business environment for medical devices and equipment is favorable in Brazil and holds promise for players who are interested in expanding into the country’s IVD market. Brazilian health professionals as well as patients are demanding innovative diagnostic products, targeting infectious diseases and cancer, aided by the country’s stabilizing economic condition and growing middle class population. Brazil's healthcare system relies on both public and private spending, with private health spending being higher at 53% in the private sector as against 47% for the public sector. The middle class, which is responsible for the country’s growing private health insurance industry, expects faster results, with test turnaround times being a priority among the patients.

As a result, there is increasing demand for advanced testing technologies, higher sensitivity and equipment that can meet the requirement for faster results. The demand for new technologies in the laboratory sector, particularly for high-sensitivity testing and high-volume testing equipment, is growing in Brazil. Additionally, increasing investments in medical R&D is further fueling the growth of the market for IVD and laboratory equipment.

The trend of consolidation in the Brazilian laboratory service industry is also stabilizing and the current providers are highly competitive. Currently, four national, or regionally dominating, laboratory service providers are operating in the country, as against around 15 large-volume labs in the early 2000s when consolidation in the industry was intense.

Related Links:
Kalorama Information

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: The QIAstat-Dx Respiratory Panel Plus has received U.S. FDA clearance (Photo courtesy of QIAGEN)

New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results

Respiratory tract infections are a major reason for emergency department visits and hospitalizations. According to the CDC, the U.S. sees up to 41 million influenza cases annually, resulting in several... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more